Posted by Michael Wonder on 04 Apr 2025
Imfinzi-based peri-operative regimen approved in the EU for resectable non-small cell lung cancer
4 April 2025 - Approval based on AEGEAN Phase 3 trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neo-adjuvant chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union for the treatment of adults with resectable non-small cell lung cancer at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
